Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor-based chemotherapy-free or low-dose chemotherapy in relapsed/refractory AML
ChiCTR2300077623Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of selinexor in acute myeloid leukemia (AML), sponsored by Tongji Hospital. Primary endpoint: Complete remission rate. Started Nov 2023; status: recruiting.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2300077623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077623.